Interaction between Comorbidity and Cancer

Extermann M. , Overcash J. , Lyman G.H. . Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 1582–1587.

Extermann M. , Yoder J. , Overcash J. . Influence of concomitant medications metabolized by cytochrome P-450 on toxicity from chemotherapy. Presented at the 8th International Conference on Geriatric Oncology; November 21-22, 2003; Rome, Italy.

Brauer P.M. , McKeown-Eyssen G.E. , Jazmaji V. . Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. Am J Epidemiol. 2002; 156: 702–713.

Le Marchand L. , Wilkens L.R. , Kolonel L.N. . Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res. 1997; 57: 4787–4794.

Hu F.B. , Manson J.E. , Liu S. . Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999; 91: 542–547.

Coughlin S.S. , Calle E.E. , Teras L.R. . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159: 1160–1167.

Colangelo L.A. , Gapstur S.M. , Gann P.H. . Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002; 11: 385–391.

Marugame T. , Lee K. , Eguchi H. . Relation of impaired glucose tolerance and diabetes mellitus to colorectal adenomas in Japan. Cancer Causes Control. 2002; 13: 917–921.

Weiss H.A. , Brinton L.A. , Potischman N.A. . Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999; 28: 816–823.

Everhart J. , Wright D. . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273: 1605–1609.

Chari S.T. , Leibson C.L. , Rabe K.G. . Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005; 129: 504–511.

Damiano J. , Bordier L. , Le Berre J.P. . Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab. 2004; 30: 203–207.

Ogawa Y. , Tanaka M. , Inoue K. . A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002; 94: 2344–2349.

Tavani A. , La Vecchia C. , Franceschi S. . Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev. 2000; 9: 59–64.

Komninou D. , Ayonote A. , Richie J.P. Jr ,. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood). 2003; 228: 396–405.

Calle E.E. , Rodriguez C. , Walker-Thurmond K. . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625–1638.

Carmichael A.R. , Bates T. . Obesity and breast cancer: a review of the literature. Breast. 2004; 13: 85–92.

Presti JC Jr . Obesity and prostate cancer. Curr Opin Urol. 2005; 15: 13–16.

Chang E.T. , Hjalgrim H. , Smedby K.E. . Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005; 97: 210–218.

Pavelka J.C. , Brown R.S. , Karlan B.Y. . Effect of obesity on survival of epithelial ovarian cancer. Cancer. 2006; 107: 1520–1524. [Epub ahead of print]

Parker E.D. , Folsom A.R. . Intentional weight loss and incidence of obesity-related cancers: the lowa Women's Health Study. Int J Obes Relat Metab Disord. 2003; 27: 1447–1452.

Yamada K. , Araki S. , Tamura M. . Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol. 1998; 27: 794–798.

Tseng T.H. , Hsu J.D. , Chu C.Y. . Promotion of colon carcinogenesis through increasing lipid peroxidation induced in rats by a high cholesterol diet. Cancer Lett. 1996; 100: 81–87.

Stathopoulos G.P. , Stergiou G.S. , Perrea-Kostarelis D.N. . Influence of 5-fluorouracil on serum lipids. Acta Oncol. 1995; 34: 253–256.

Wang W. , Collie-Duguid E. , Cassidy J. . Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett. 2002; 531: 415–420.

Cohen H.J. , Harris T. , Pieper C.F. . Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003; 114: 180–187.

Cerhan J.R. , Anderson K.E. , Janney C.A. . Association of aspirin and other nonsteroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003; 106: 784–788.

Smedby K.E. , Hjalgrim H. , Askling J. . Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006; 98: 51–60.

Zintzaras E. , Voulgarelis M. , Moutsopoulos H.M. . The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165: 2337–2344.

Fryzek J.P. , Mellemkjaer L. , McLaughlin J.K. . Cancer risk among patients with finger and hand joint and temporo-mandibular joint prostheses in Denmark. Int J Cancer. 1999; 81: 723–725.

Coakley G. , Brooks D. , Iqbal M. . Major histocompability complex haplotypic associations with Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1∗0401. Rheumatology (Oxford). 2000; 39: 393–398.

Thomas E. , Symmons D.P. , Brewster D.H. . National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003; 30: 958–965.

Collin P. , Reunala T. , Pukkala E. . Coeliac disease-associated disorders and survival. Gut. 1994; 35: 1215–1218.

Ioannidis J.P. , Vassiliou V.A. , Moutsopoulos H.M. . Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002; 46: 741–747.

De Re V. , De Vita S. , Gasparotto D. . Salivary gland B-cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur J Immunol. 2002; 32: 903–910.

Davidson B.K. , Kelly C.A. , Griffiths I.D. . Primary Sjögren's syndrome in the North East of England: a long-term followup study. Rheumatology (Oxford). 1999; 38: 245–253.

Sultan S.M. , Ioannou Y. , Isenberg D.A. . Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford). 2000; 39: 1147–1152.

Nived O. , Bengtsson A. , Jonsen A. . Malignancies during followup in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus. 2001; 10: 500–504.

Mellemkjaer L. , Andersen V. , Linet M.S. . Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 761–768.

Cibere J. , Sibley J. , Haga M. . Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001; 10: 394–400.

Abu-Shakra M. , Gladman D.D. , Urowitz M.B. . Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996; 39: 1050–1054.

Ramsey-Goldman R. , Mattai S.A. , Schilling E. . Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998; 46: 217–222.

Bateman H. , Yacizi Y. , Leff L. . Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus. 2000; 9: 542–544.

Mariette X. , Cazals-Hatem D. , Warszawki J. . Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99: 3909–3915.

Kamel O.W. , Holly E.A. , van de Rijn M. . A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol. 1999; 26: 1676–1680.

Fraser A.G. , Orchard T.R. , Robinson E.M. . Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16: 1225–1232.

Smith K.J. , Skelton H.G. . Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necorsis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001; 45: 953–956.

Brown S.L. , Greene M.H. , Gershon S.K. . Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum. 2002; 46: 3151–3158.

Cristofanilli M. , Yamamura Y. , Kau S.W. . Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005; 103: 1122–1128.

Schwartzbaum J. , Jonsson F. , Ahlbom A. . Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003; 106: 423–428.

Brenner A.V. , Linet M.S. , Fine H.A. . History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer. 2002; 99: 252–259.

González-Péerez A. , García Rodríguez L.A. , López-Ridaura R. . Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and the rectum: a meta-analysis. BMC Cancer. 2003; 3: 28.

Eaden J. . Review article: the data supporting a role for aminosalicy-lates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18(suppl 2): 15–21.

Rahme E. , Barkun A.N. , Toubouti Y. . The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003; 125: 404–412.

Chan A.T. , Giovannucci E.L. , Meyerhardt J.A. . Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005; 294: 914–923.

Sandler R.S. , Halabi S. , Baron J.A. . A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348: 883–890.

Baron J.A. , Cole B.F. , Sandler R.S. . A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348: 891–899.

Benamouzig R. , Deyra J. , Martin A. . Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003; 125: 328–336.

Steinbach G. , Lynch P.M. , Phillips R.K. . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342: 1946–1952.

Phillips R.K. , Wallace M.H. , Lynch P.M. . A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002; 50: 857–860.

Giardiello F.M. , Yang V.W. , Hylind L.M. . Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002; 346: 1054–1059.

Khuder S.A. , Mutgi A.B. . Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001; 84: 1188–1192.

Harris R.E. , Chlebowski R.T. , Jackson R.D. . Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003; 63: 6096–6101.

Harris R.E. , Beebe-Donk J. , Alshafie G.A. . Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006; 6: 27.

Bonovas S. , Filioussi K. , Sitaras N.M. . Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol. 2005; 60: 194–203.

Chang E.T. , Smedby K.E. , Hjalgrim H. . Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol. 2005; 162: 965–974. Epub 2005 Sep 28.

Hundal R.S. , Petersen K.F. , Mayerson A.B. . Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002; 109: 1321–1326.

Cauley J.A. , Zmuda J.M. , Lui L.Y. . Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt). 2003; 12: 749–756.

Graaf M.R. , Beiderbeck A.B. , Egberts A.C. . The risk of cancer in users of statins. J Clin Oncol. 2004; 22: 2388–2394.

Mortimer J.E. . The protective effects of statins on the incidence of breast cancer in older women. Presented at the 8th International Conference on Geriatric Oncology; November 21-22, 2003; Rome, Italy.

Bjerre L.M. , LeLorier J. . Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001; 110: 716–723.

Beck P. , Wysowski D.K. , Downey W. . Statin use and the risk of breast cancer. J Clin Epidemiol. 2003; 56: 280–285.

Coogan P.F. , Rosenberg L. , Palmer J.R. . Statin use and the risk of breast and prostate cancer. Epidemilogy. 2002; 13: 262–267.

Kaye J.A. , Meier C.R. , Walker A.M. . Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer. 2002; 86: 1436–1439.

Jacobs E.J. , Rodriguez C. , Brady K.A. . Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006; 98: 69–72.

Dale K.M. , Coleman C.I. , Henyan N.N. . Statins and cancer risk: a meta-analysis. JAMA. 2006; 295: 74–80.

Bonovas S. , Filioussi K. , Tsavaris N. . Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23: 8606–8612. Epub 2005 Oct 31.

Greenfield S. , Blanco D.M. , Elashoff R.M. . Patterns of care related to age of breast cancer patients. JAMA. 1987; 257: 2766–2770.

Meyerhardt J.A. , Catalano P.J. , Haller D.G. . Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003; 21: 433–440.

Little S.A. , Jarnagin W.R. , DeMatteo R.P. . Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg. 2002; 6: 88–94.

Meyerhardt J.A. , Catalano P.J. , Haller D.G. . Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003; 98: 484–495.

Merrick G.S. , Butler W.M. , Wallner K.E. . Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005; 65: 95–100.

Enger S.M. , Greif J.M. , Polikoff J. . Body weight correlates with mortality in early stage breast cancer. Arch Surg. 2004; 139: 954–960.

Hammarsten J. , Högstedt B. . Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005; 41: 2887–2895. Epub 2005 Oct 20.

Goodwin P.J. , Ennis M. , Pritchard Kl Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002; 20: 42–51.

Ford E.S. , Giles W.H. , Dietz W.H. . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356–359.

Chan J.M. , Latini D.M. , Cowan J. . History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaP-SURE (United States). Cancer Causes Control. 2005; 16: 789–797.

Mikuls T.R. , Endo J.O. , Puumala S.E. . Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006; 24: 1597–1602. Epub 2006 Mar 6.

Smith M.R. , Manola J. , Kaufman D.S. . Rosiglitazone versus placebo in men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004; 101: 1569–1574.